Subscribe to RSS
Download PDF
DOI: 10.1055/a-2646-9889
Behandlung von Patientinnen[1] mit frühem Mammakarzinom
19. Internationaler St.-Gallen-Konsens vor dem Hintergrund deutscher Therapieempfehlungen diskutiertTreatment of Patients with Early Breast Cancer19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment RecommendationsAuthors
Zusammenfassung
Die diesjährige 19. St.-Gallen-(SG-)Konsensus-Konferenz zur Behandlung von Patientinnen mit frühem Mammakarzinom (SGBCC: St. Gallen Breast Cancer Conference) basierte auf zahlreichen fiktiven Fallbeispielen mit jeweils unterschiedlichen Variablen, um der zunehmend personalisierten Therapieentscheidung beim primären – frühen – Mammakarzinom gerecht zu werden. Stärker denn je fließen nicht nur der Mammakarzinom-Subtyp, der Allgemeinzustand und das Lebensalter bzw. die Lebenserwartung als individuelle Faktoren in die Therapieentscheidung ein, sondern auch unterschiedliche molekulare und genetische Variablen. Wie schon in den vergangenen Jahren hat auch dieses Jahr eine deutsche Arbeitsgruppe führender Brustkrebsexpertinnen und -experten die Ergebnisse der internationalen SGBCC 2025 vor dem Hintergrund der deutschen Therapieempfehlungen – speziell der erst kürzlich (2025) aktualisierten Therapieempfehlungen der Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) – für den Klinikalltag in Deutschland diskutiert. Die deutschen Therapieempfehlungen der AGO Mamma 2025 basieren auf der aktuell vorhandenen Evidenz. Der Abgleich mit dem klinischen Vorgehen in Deutschland bewährt sich seit Jahren, da sich das SGBCC-Panel aus Expertinnen und Experten unterschiedlicher Länder und Fachdisziplinen zusammensetzt, weshalb länderspezifische Besonderheiten in die SGBCC-Empfehlungen einfließen können.
Abstract
This yearʼs 19th St. Gallen (SG) consensus conference on the treatment of patients with early breast cancer (SGBCC: St. Gallen Breast Cancer Conference) is based on numerous patient examples, each with different variables, to reflect the increasingly personalized treatment decision for early breast cancer. More than ever, not only breast cancer subtype, performance status, age and life expectancy are considered as individual factors, but various molecular and genetic variables are also part of the treatment decision. In this manuscript, the SGBCC voting results are discussed by a German group of breast cancer specialists in the context of the recently (2025) updated treatment recommendations of the Commission of the Gynecological Oncology Working Group (AGO Mamma). The German treatment recommendations are based on current evidence. As the international panel of the SGBCC consists of experts from different countries and disciplines, the votes represent an international cross-section of opinions. Therefore, it is useful to discuss the voting results with respect to current German treatment guidelines.
Schlüsselwörter
St.-Gallen-Konsens 2025 - frühes Mammakarzinom - Genetik - Operation - Strahlentherapie - (neo)adjuvante Systemtherapie - NachsorgeKey words
St. Gallen Consensus 2025 - early breast cancer - genetics - surgery - radiotherapy - (neo)adjuvant systemic therapy - survivorship1 Da mit überwiegender Mehrheit Frauen am Brustkrebs erkranken, wird im Manuskript von „Patientinnen“ gesprochen. So nicht extra erwähnt, gelten die Aussagen auch für Männer mit Brustkrebs.
* Writing Committee.
** St.‑Gallen‑Panelmitglieder.
P Patientenvertreterin.
Publication History
Received: 29 April 2025
Accepted after revision: 12 May 2025
Article published online:
24 September 2025
© 2025. This article was originally published by Thieme in Geburtsh Frauenheilk 2025; 85: 677–693 as an open access article under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
Literatur
- 1 AGO Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome. März 2025. Accessed June 14, 2025 at: https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2025/AGO_2025D_Gesamtdatei.pdf
- 2 Park-Simon T-W, Müller V, Albert U-S. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025. Breast Care (Basel) 2025; 1-30
- 3 Ditsch N. et al. Update Breast Cancer 2025 Part 1 – Expert Opinions of Early Stage Breast Cancer Therapies. Geburtshilfe Frauenheilkd 2025 (submitted).
- 4 Meattini I, Coles CE, Tramm T. et al. Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review. JAMA Oncol 2025; 11: 329-339
- 5 Reimer T, Stachs A, Veselinovic K. et al. Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial. N Engl J Med 2025; 392: 1051-1064
- 6 de Boniface J, Filtenborg Tvedskov T, Rydén L. et al. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. N Engl J Med 2024; 390: 1163-1175
- 7 Kunkler I. Does postmastectomy radiotherapy in “intermediate-risk” breast cancer impact overall survival? 10 year results of the BIG 2-04 MRC randomized trial on behalf of the SUPREMO trial investigators. Texas/USA: San Antonio;
- 8 Krug D, Baumann R, Combs SE. et al. Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward. Strahlenther Onkol 2021; 197: 269-280
- 9 Murray Brunt A, Haviland JS, Wheatley DA. et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613-1626
- 10 Borm KJ, Hörner-Rieber J, Duma NM. et al. De-escalation strategies in early breast cancer: implications of sentinel lymph node biopsy omission for adjuvant radiotherapy. Strahlenther Onkol 2025;
- 11 Mamounas EP, Bandos H, White JR. et al. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). JCO 2019; 37: TPS600
- 12 Boughey JC, Suman VJ, Mittendorf EA. et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310: 1455-1461
- 13 Meattini I. Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial [GS2-01]. Texas/USA: San Antonio; 2024
- 14 Schmid P, Cortes J, Dent R. et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 2024; 391: 1981-1991
- 15 Tarantino P, Leone J, Vallejo CT. et al. Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): A population-based study. JCO 2023; 41: 510
- 16 Mukhtar RA, Hoskin TL, Habermann EB. et al. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB). Ann Surg Oncol 2021; 28: 5867-5877
- 17 de Gregorio A, Janni W, Friedl TWP. et al. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer 2022; 126: 1715-1724
- 18 Gougis P, Hamy A-S, Jochum F. et al. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns. JAMA Netw Open 2024; 7: e245625
- 19 Tutt A, Garber JE, Kaufman B. et al. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. JCO 2021; 39: LBA1
- 20 Garber JE. Pre-specified analyses of IDFS, DDFS and OS10 years from First Patient In (FPI) in the OlympiA trial of adjuvant olaparib in germline BRCA1/2 mutation-associated breast cancer [GS1-09]. Texas/USA: San Antonio; 2024
- 21 Rugo HS, Llombart-Cussac A, Andre F. et al. KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs. pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). JCO 2020; 38: TPS596
- 22 Rugo H, Robson M, Im S-A. et al. Abstract GS01-05: Pembrolizumab + Olaparib vs. Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study. Cancer Research 2024; 84: GS01-05
- 23 Nederlof I. Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). Barcelona/Spanien: 2024
- 24 Tolaney SM, Tarantino P, Graham N. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 2023; 24: 273-285
- 25 Geyer CE, Untch M, Huang C-S. et al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. N Engl J Med 2025; 392: 249-257
- 26 Loibl S, Huang C-S, Mano MS. et al. Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. NPJ Breast Cancer 2022; 8: 106
- 27 Waks AG, Villacampa G, Brunet LP. et al. 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies. ESMO Open 2023; 8: 101465
- 28 Villacampa G, Tung NM, Pernas S. et al. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann Oncol 2023; 34: 783-795
- 29 Coates AS, Winer EP, Goldhirsch A. et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533-1546
- 30 Lux MP, Ciani O, Dunlop WCN. et al. The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. Cancer Manag Res 2021; 13: 8457-8471
- 31 Harbeck N, Gluz O, Kuemmel S. et al. Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0–3 lymph nodes), Recurrence Score < 26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial. Cancer Res 2021; 81 (Suppl. 04) GS4-04
- 32 Mengel M, von Wasielewski R, Wiese B. et al. Inter-laboratory and interobserver reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 2002; 198: 292-299
- 33 Johnston SRD, Harbeck N, Hegg R. et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). JCO 2020; 38: 3987-3998
- 34 Slamon D, Lipatov O, Nowecki Z. et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 2024; 390: 1080-1091
- 35 Robson ME, Tung N, Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physicianʼs choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30: 558-566
- 36 Reimer T, Gluz O, Nitz U. et al. Prospektive Phase-III PlanB-Studie: 5-Jahres-Daten zum prognostischen Stellenwert von 21-Gen Recurrence-Score, zentralpathologischem Grading, ER, PR, Ki-67 Review beim frühem Hochrisiko HR+/HER2- negativen Mammakarzinom. Senologie 2016;
- 37 Kalinsky K, Barlow WE, Gralow JR. et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 2021; 385: 2336-2347
- 38 Janni W, Untch M, Harbeck N. et al. Systematic literature review and triallevel meta-analysis of aromatase inhibitors vs. tamoxifen in patients with HR+/HER2- early breast cancer. Breast 2025; 81: 104429
- 39 Hortobagyi GN, Lacko A, Sohn J. et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol 2025; 36: 149-157
- 40 Untch M, Pérol D, Mayer EL. et al. Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis. Eur J Cancer 2024; 202: 113977
- 41 Fasching PA, Stroyakovskiy D, Yardeley D. et al. Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2- early breast cancer (EBC): 4-year outcomes from the NATALEE trial [LBA13]. Ann Oncol 2025; 35 (Suppl. 02) S1207
- 42 Michel LL, Schwarz D, Romar P. et al. Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial. JAMA Oncol 2025;
- 43 Khan SA, Zhao F, Goldstein LJ. et al. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). JCO 2022; 40: 978-987
- 44 Piroth MD, Krug D, Feyer P. et al. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective. Strahlenther Onkol 2022; 198: 601-611